{"schemaVersion":1,"research":true,"symbol":"dhr","name":"Danaher","topic":"moat","path":"/stock/dhr/moat","status":"published","version":6,"updatedAt":"2026-10-19T15:46:47.000Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"uncertain","summary":"Danaher has demonstrated recurring consumables demand and multiyear contractual customer commitments, alongside specialized technologies and workflow offerings. These establish current commercial strengths, but the supplied passages do not establish durable switching barriers or sustained superiority over alternatives. Pricing power is mixed: Biotechnology achieved price increases, Life Sciences pricing was insignificant in first-half 2026, and Diagnostics suffered procurement-driven price declines. A durable moat remains unestablished; the evidence does not establish a broadly weak competitive position.","advantages":[{"mechanism":"switching_costs","claim":"Noncancelable orders and minimum purchases under long-term consumable arrangements provide current contractual demand protection. Workflow instruments, associated consumables and process services offer a plausible source of switching friction, but actual replacement costs and customer lock-in are not demonstrated.","durability":"Protection extends over disclosed contractual obligations. Remaining performance obligations increased from $4.3 billion at year-end 2024 to $5.2 billion at year-end 2025, but their composition and recognition schedule do not establish durable retention after contracts expire.","risks":"Customer funding constraints and variable testing demand have reduced sales despite recurring offerings. Contractual commitments do not establish pricing discretion or inability to substitute competing products.","invalidation":"The switching-cost hypothesis would be undermined by customers replacing platforms without material disruption or expense, minimum commitments expiring without repeat purchases, or persistent consumables losses attributable to substitution.","competitors":[],"evidenceIds":["e1","e2","e3","e4","e5","e6","e7","e8"],"counterEvidenceIds":["e9","e10","e11"]},{"mechanism":"intangible_assets","claim":"Danaher owns intellectual property and supplies specialized scientific technologies, technical support and process services. These are current differentiation resources, but issuer leadership descriptions and product breadth do not establish an enduring competitive advantage.","durability":"Potential durability depends on continued innovation, effective intellectual property protection and customer acceptance. The catalog provides no product-specific exclusivity periods or comparative performance evidence sufficient to establish a moat.","risks":"Danaher explicitly acknowledges that intellectual property does not always provide significant advantage. A realized trade-name impairment demonstrates that intangible asset value can erode. Procurement pressure has also produced actual price declines.","invalidation":"The intangible-advantage hypothesis would be undermined by successful design-arounds, loss of relevant protection, demonstrated equivalent alternatives winning customers, or persistent price concessions without compensating demand.","competitors":[],"evidenceIds":["e5","e12","e13","e14"],"counterEvidenceIds":["e15","e16","e17","e18"]}],"evidence":[{"id":"e1","sourceId":"filing-1","location":"Revenue note: composition of remaining performance obligations","excerpt":"Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term consumable supply arrangements, extended warranty and service and other long-term contracts."},{"id":"e2","sourceId":"filing-1","location":"Revenue note: cancellation rights excluded from remaining performance obligations","excerpt":"While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote."},{"id":"e3","sourceId":"filing-1","location":"Revenue note: year-end 2025 remaining performance obligations","excerpt":"As of December 31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $5.2 billion."},{"id":"e4","sourceId":"filing-4","location":"Revenue note: year-end 2024 remaining performance obligations","excerpt":"As of December 31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.3 billion."},{"id":"e5","sourceId":"filing-1","location":"Business: bioprocessing automation, training and process services","excerpt":"The bioprocessing business’ offerings in data connectivity and automation, advanced process training, process development services and equipment services are designed to help customers develop more optimized, compliant processes and ensure continuous performance."},{"id":"e6","sourceId":"filing-1","location":"Business: instruments and associated consumables","excerpt":"Key product areas include sample preparation equipment such as centrifugation and consumables; liquid handling automation instruments and associated consumables; flow cytometry instrumentation and associated antibodies and reagents; particle counting and characterization instrumentation; and genomic sample preparation."},{"id":"e7","sourceId":"filing-2","location":"MD&A: first-half 2026 Biotechnology consumables demand","excerpt":"The year-over-year increase in total segment core sales in the six-month period ended June 26, 2026 was led by increased sales of consumables, partially offset by lower equipment sales."},{"id":"e8","sourceId":"filing-2","location":"MD&A: first-half 2026 Life Sciences demand","excerpt":"The year-over-year increase in total segment core sales in both the three and six-month periods ended June 26, 2026 was driven by an increase in consumables sales and to a lesser extent higher demand for equipment."},{"id":"e9","sourceId":"filing-1","location":"Revenue note: minimum commitments do not cover all consumable arrangements","excerpt":"These remaining performance obligations do not include revenue from contracts with customers with an original term of one year or less, revenue from long-term consumable supply arrangements with no minimum purchase requirements or revenue expected from purchases made in excess of the minimum purchase requirements or revenue from equipment leased to customers."},{"id":"e10","sourceId":"filing-1","location":"MD&A: 2025 Life Sciences customer demand weakness","excerpt":"41 Table of Contents The year-over-year decrease in segment core sales was led by the life science consumables business, primarily in North America, driven by lower demand for the plasmids and mRNA product lines at two large customers and lower funding levels at emerging biotechnology and academic research customers."},{"id":"e11","sourceId":"filing-2","location":"MD&A: realized respiratory testing demand decline","excerpt":"The decreased demand for respiratory tests was driven primarily by a less severe respiratory season in the first half of 2026 compared to the comparable period of 2025."},{"id":"e12","sourceId":"filing-1","location":"Risk factors: intellectual property's role in differentiation","excerpt":"Many of the markets we serve are technology-driven, and as a result intellectual property rights play a significant role in product development and differentiation."},{"id":"e13","sourceId":"filing-1","location":"Risk factors: owned and licensed intellectual property","excerpt":"We own numerous patents, trademarks, copyrights, trade secrets and other intellectual property and licenses to intellectual property owned by others, which in aggregate are important to our business."},{"id":"e14","sourceId":"filing-1","location":"Business: Biotechnology customer selection factors","excerpt":"Customers served by the Biotechnology segment select products based on several factors, including product quality and reliability, the product’s capacity to enhance productivity and flexibility, innovation (particularly productivity and sensitivity improvements), product performance and ergonomics, access to an advanced technical expertise, service and support network and the other factors described under the heading “Competition” below."},{"id":"e15","sourceId":"filing-1","location":"Risk factors: limitations of intellectual property advantage","excerpt":"The intellectual property rights that we obtain, however, are not always sufficiently broad and do not always provide us a significant competitive advantage, and patents may not be issued for pending or future patent applications owned by or licensed to us."},{"id":"e16","sourceId":"filing-2","location":"Intangible assets note: realized $432 million trade-name impairment","excerpt":"The Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) related to the trade name for both the three and six-months ended June 27, 2025, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statement of Earnings."},{"id":"e17","sourceId":"filing-2","location":"Intangible assets note: impairment rationale and lower demand","excerpt":"The amount of the impairment was primarily attributable to the conclusion that the trade name was no longer indefinite-lived, as well as, by current lower levels of demand in the genomics market, including at emerging biotechnology customers and at two large customers."},{"id":"e18","sourceId":"filing-1","location":"MD&A: 2025 Diagnostics price decreases","excerpt":"Divestitures\nCore sales growth (non-GAAP)\n3.0 \nPrice decreases in the segment of 1.0%, primarily attributable to the volume-based procurement program and healthcare reimbursement changes in China and to a lesser extent, sales promotions, negatively impacted the year-over-year change in sales during 2025 and are reflected as a component of core sales above."},{"id":"e19","sourceId":"filing-1","location":"MD&A: consolidated 2025 realized price contribution","excerpt":"Price increases contributed 0.5% to sales growth on a year-over-year basis and are reflected as a component of core sales growth above."},{"id":"e20","sourceId":"filing-2","location":"MD&A: Biotechnology second-quarter and first-half 2026 realized pricing","excerpt":"Comparable 2025 Period Total sales growth (GAAP) 4.0 % 7.5 % Impact of: Currency exchange rates (1.5) % (3.0) % Core sales growth (non-GAAP) 2.5 % 4.5 % Price increases in the segment contributed 1.5% to sales growth on a year-over-year basis in both periods and are reflected as a component of core sales above."},{"id":"e21","sourceId":"filing-2","location":"MD&A: Life Sciences second-quarter and first-half 2026 pricing","excerpt":"Comparable 2025 Period Total sales growth (GAAP) 5.5 % 4.5 % Impact of: Currency exchange rates — % (1.5) % Core sales growth (non-GAAP) 5.5 % 3.0 % Price increases did not have a significant impact on sales growth on a year-over-year basis during both the three and six-month periods ended June 26, 2026 and are reflected as a component of core sales above."},{"id":"e22","sourceId":"filing-1","location":"MD&A: consolidated 2025 operating margin decline","excerpt":"Operating Profit Performance\nOperating profit margins decreased 130 basis points from 20.4% for the year ended December 31, 2024 to 19.1% for the year ended December 31, 2025."},{"id":"e23","sourceId":"filing-2","location":"Segment note: first-half 2026 segment results and prior-year impairments","excerpt":"Detailed segment data for the three and six-month periods ended June 26, 2026 and June 27, 2025 is as follows ($ in millions): Biotechnology Life Sciences Diagnostics Total Reportable Segments Other(a) Total For the Three-Month Period Ended June 26, 2026: Sales $ 1,920 $ 1,879 $ 2,466 $ 6,265 $ — $ 6,265 Less: Depreciation (40) (48) (107) (195) (1) (196) Amortization of intangible assets (231) (151) (81) (463) — (463) Other segment items(c) (1,093) (1,436) (1,862) (4,391) (88) (4,479) Operating profit $ 556 $ 244 $ 416 $ 1,216 $ (89) $ 1,127 For the Three-Month Period Ended June 27, 2025: Sales $ 1,850 $ 1,777 $ 2,309 $ 5,936 $ — $ 5,936 Less: Depreciation (38) (45) (100) (183) (2) (185) Amortization of intangible assets (228) (150) (48) (426) — (426) Impairments(b) — (432) — (432) — (432) Other segment items(c) (1,053) (1,389) (1,607) (4,049) (84) (4,133) Operating profit (loss) $ 531 $ (239) $ 554 $ 846 $ (86) $ 760 11 Table of Contents Biotechnology Life Sciences Diagnostics Total Reportable Segments Other(a) Total For the Six-Month Period Ended June 26, 2026: Sales $ 3,717 $ 3,616 $ 4,883 $ 12,216 $ — $ 12,216 Less: Depreciation (80) (96) (209) (385) (4) (389) Amortization of intangible assets (465) (303) (129) (897) — (897) Other segment items(c) (2,082) (2,748) (3,455) (8,285) (174) (8,459) Operating profit $ 1,090 $ 469 $ 1,090 $ 2,649 $ (178) $ 2,471 For the Six-Month Period Ended June 27, 2025: Sales $ 3,462 $ 3,457 $ 4,758 $ 11,677 $ — $ 11,677 Less: Depreciation (72) (90) (200) (362) (4) (366) Amortization of intangible assets (441) (299) (96) (836) — (836) Impairments(b) (15) (432) — (447) — (447) Other segment items(c) (1,962) (2,674) (3,190) (7,826) (168) (7,994) Operating profit (loss) $ 972 $ (38) $ 1,272 $ 2,206 $ (172) $ 2,034 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance."},{"id":"e24","sourceId":"filing-1","location":"Risk factors: purchasing consolidation and competitive procurement","excerpt":"•Governmental and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services, centralizing purchasing, limiting the number of vendors that may participate in purchasing programs, forming group purchasing organizations, strategic alliances and integrated health delivery networks and pursuing consolidation to improve their purchasing leverage, using competitive bid processes to procure healthcare products and services and investing in healthcare practices to increase their control over healthcare spending."},{"id":"e25","sourceId":"filing-2","location":"MD&A: continuing but moderating China procurement pricing effects","excerpt":"The core sales decrease in China in both periods was partially attributable to the pricing impact of China’s volume-based procurement program and healthcare reimbursement changes, which has moderated as the Company began to move beyond the most significant year-over-year impacts of these changes that began in late 2024."},{"id":"e26","sourceId":"filing-3","location":"Proxy business highlights: actual 2025 research and capital investment","excerpt":"Notwithstanding these hurdles, we continued to invest in Danaher’s future growth, investing approximately $1.6 billion in research and development and approximately $1.2 billion in capital expenditures to support future core growth."},{"id":"e27","sourceId":"filing-3","location":"Proxy business highlights: 2025 cash generation and shareholder distributions","excerpt":"Even as we made these significant growth investments, in 2025 we returned approximately $4.0 billion to our shareholders through stock buybacks and dividends and generated the following financial returns: $24.6 Billion $4.7 Billion $6.4 Billion 2025 Sales 2025 Operating Profit 2025 Operating Cash Flow Long-Term Performance The graph below reflects Danaher's compound average annual shareholder return over the past twenty-five years, compared to the S&P 500 and the Health Care Select Sector SPDR Fund: (1) XLV = The Health Care Select Sector SPDR Fund 2026 Notice of Annual Meeting and Proxy Statement 5 Table of Contents Corporate Governance Overview Our Board recognizes that Danaher’s success over the long-term requires a robust framework of corporate governance that serves the best interests of all our shareholders and promotes robust risk oversight."},{"id":"e28","sourceId":"filing-2","location":"Cash flow disclosures: first-half 2026 acquisition spending and capital expenditures","excerpt":"($ in millions, except per share amount)\nASSETS\nCurrent assets:\nCash and equivalents\n4,348 \n4,615 \nTrade accounts receivable, less allowance for doubtful accounts of $121 and $114, respectively\n3,965 \n3,913 \nInventories:\nFinished goods\n1,813 \n1,287 \nWork in process\n537 \nRaw materials\n910 \n733 \nTotal inventories\n3,260 \n2,489 \nPrepaid expenses and other current assets\n1,808 \n1,739 \nTotal current assets\n13,381 \n12,756 \nProperty, plant and equipment, net of accumulated depreciation of $4,915 and $4,767, respectively\n5,825 \n5,531 \nOther long-term assets\n4,389 \n4,209\nCash flows from operating activities:\nNoncash items:\nAmortization of acquisition-related inventory fair value step-up\nStock-based compensation expense\nInvestment losses and pretax gain on sale of product line\n125 \nImpairment charges\nChange in trade accounts receivable, net\n137 \n134 \nChange in inventories\n(248)\nChange in trade accounts payable\n(79)\n(111)\nChange in prepaid expenses and other assets\n(99)\nChange in accrued expenses and other liabilities\n(571)\n(474)\nNet cash provided by operating activities\n2,856 \n2,637 \nCash flows from investing activities:\nCash paid for acquisitions\n(9,843)\nPayments for additions to property, plant and equipment\n(506)\n(493)\nProceeds from sales of property, plant and equipment"},{"id":"e29","sourceId":"filing-2","location":"Risk factors: debt incurred for Masimo acquisition","excerpt":"For example, the Company incurred debt to finance a portion of the purchase price for our acquisition of Masimo."},{"id":"e30","sourceId":"filing-2","location":"Equity note: actual first-half 2026 repurchases","excerpt":"During both the three and six-month periods ended June 26, 2026, the Company repurchased approximately 5.0 million shares of the Company’s common stock for $903 million, inclusive of excise taxes."},{"id":"e31","sourceId":"filing-2","location":"Equity note: actual compensation share issuance","excerpt":"The following table summarizes the activity of the Company’s issued shares (shares in millions): Three-Month Period Ended Six-Month Period Ended June 26, 2026 June 27, 2025 June 26, 2026 June 27, 2025 Common stock - shares issued: Balance, beginning of period 888.0 885.6 886.9 884.3 Common stock-based compensation awards 0.2 0.3 1.3 1.6 Balance, end of period 888.2 885.9 888.2 885.9 Stock-Based Compensation For a full description of the Company’s stock-based compensation programs, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2025 included in the Company’s 2025 Annual Report."},{"id":"e32","sourceId":"filing-3","location":"Proxy compensation: vesting, holding, ownership, clawback and hedging policies","excerpt":"As a result, the Committee regularly reviews external executive compensation practices and trends and incorporated best practices into our 2025 executive compensation program: What We Do What We Don't Do Multi-year vesting requirement for stock options, and three-year performance period plus further two-year holding period for Performance Stock Units (\"PSUs\") No tax gross-up provisions (except as applicable to management employees generally such as our relocation policy) Incentive compensation programs feature multiple performance measures aligned with Company strategic performance metrics No dividends/dividend equivalents paid on unvested equity awards Short-term and long-term performance metrics that incorporate our absolute performance and relative performance versus peer companies No “single trigger” change of control benefits Rigorous, no-fault clawback policies that are triggered even in the absence of wrongdoing No defined benefit pension program for any NEO Minimum one-year vesting requirement for 95% of shares granted under the Company’s stock plan No hedging of Danaher securities permitted Robust stock ownership requirements for all executive officers No long-term incentive compensation is denominated or paid in cash (other than PSU dividend accruals) Limited perquisites and a cap on CEO/CFO personal aircraft usage No above-market returns on deferred compensation plans Independent compensation consultant that performs no other services for the Company 2026 Notice of Annual Meeting and Proxy Statement 9 Table of Contents Named Executive Officers’ 2025 Compensation The following table sets forth the 2025 compensation of our named executive officers."},{"id":"e33","sourceId":"filing-3","location":"Proxy compensation: actual 2025 annual equity award mix","excerpt":"Equity Award Mix Annual Equity Awards With respect to each NEO's 2025 annual equity awards, one-half of the target award value was delivered as stock options and one-half as PSUs."},{"id":"e34","sourceId":"filing-3","location":"Proxy compensation: implementation status of 2026 changes","excerpt":"Following is a summary of these changes, each of which has been implemented with respect to Danaher’s 2026 executive compensation program:"},{"id":"e35","sourceId":"filing-3","location":"Proxy compensation: revised 2026 equity award mix","excerpt":"•Long-term incentive compensation. \n◦In our long-term incentive compensation program, we added time-vested RSUs to the program and revised the annual award mix to 60% PSUs, 20% stock options and 20% time-vested RSUs."},{"id":"e36","sourceId":"filing-3","location":"Proxy compensation: revised relative TSR and adjusted EPS performance criteria","excerpt":"◦With respect to our PSU awards in particular, we (1) reduced the weighting of relative total shareholder return (\"TSR\") performance from 100% to 50%, changed the performance group for this metric from the S&P 500 to the S&P 500 Health Care Index, and correlated threshold (50%) level payout to 25th percentile relative TSR performance and target (100%) level payout to 50th percentile performance, and (2) added a 3-year adjusted EPS target (at a 50% weighting)."},{"id":"e37","sourceId":"filing-1","location":"Independent auditor opinion: effective year-end 2025 financial reporting controls","excerpt":"In our opinion, Danaher Corporation and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria."},{"id":"e38","sourceId":"filing-3","location":"Proxy governance: Board reviews of capital allocation and performance","excerpt":"On an annual basis the Board also reviews the Company’s human capital, risk assessment/risk management, compliance and sustainability programs as well as the Company’s operating budget, and at meetings occurring throughout the year the Board reviews acquisitions, strategic investments and other capital allocation topics as well as the Company’s operating and financial performance, among other matters."},{"id":"e39","sourceId":"filing-3","location":"Proxy governance: Finance Committee meeting activity","excerpt":"The Finance Committee did not meet in 2025."},{"id":"e40","sourceId":"filing-3","location":"Related-party transactions: control of aircraft entities","excerpt":"Joust II and Stonehavens are controlled by Mitchell Rales, and Joust III is controlled by Steven Rales."},{"id":"e41","sourceId":"filing-3","location":"Related-party transactions: uncompensated aircraft management services","excerpt":"FJ900 receives no compensation for its services under the management agreements."},{"id":"e42","sourceId":"filing-3","location":"Related-party transactions: asserted shared-cost benefits","excerpt":"Having FJ900 perform management services for all of these aircraft enables Danaher and the Joust entities to share certain fixed expenses relating to the use, maintenance, storage, operation and supervision of their respective aircraft and utilize joint purchasing or joint bargaining arrangements where applicable and appropriate, allowing each party to benefit from efficiencies of scale and cost savings."},{"id":"e43","sourceId":"filing-2","location":"MD&A: actual second-quarter 2026 revenue and core growth","excerpt":"29 Table of Contents Business Performance and Outlook During the second quarter of 2026, the Company’s overall revenues and core sales increased 5.5% and 3.0%, respectively, compared to the comparable period of 2025."},{"id":"e44","sourceId":"filing-8","location":"Cash flow reconciliation: first-half 2026 operating cash flow and investment","excerpt":"RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES\n(continued)\nCash Flow and Free Cash Flow\n($ in millions) \nThree-Month Period Ended\nYear-over-Year Change\nSix-Month Period Ended\nYear-over-Year Change\nJune 26, 2026\nJune 27, 2025\nJune 26, 2026\nJune 27, 2025\nTotal Cash Flow:\nNet cash provided by operating activities (GAAP)\n$\n1,534 \n$\n1,338 \n$\n2,856 \n$\n2,637 \nTotal cash used in investing activities (GAAP)\n$\n(10,147)\n$\n(258)\n$\n(10,396)\n$\n(500)\nTotal cash provided by (used in) financing activities (GAAP)\n$\n7,273 \n$\n(247)\n$\n7,319 \n$\n(1,502)\nFree Cash Flow:\nNet cash provided by operating activities (GAAP)\n$\n1,534 \n$\n1,338 \n~ 14.5 \n%\n$\n2,856 \n$\n2,637 \n~ 8.5 \n%\nLess: payments for additions to property, plant & equipment (capital expenditures) (GAAP)\n(269)\n(248)\n(506)\n(493)\nPlus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)\n— \n4 \n— \n10 \nFree cash flow (non-GAAP)\n$\n1,265 \n$\n1,094 \n~ 15.5 \n%\n$\n2,350 \n$\n2,154 \n~ 9.0 \n%\nOperating Cash Flow to Net Earnings Conversion Ratio:"},{"id":"e45","sourceId":"filing-7","location":"Succession announcement: appointment effective October 1, 2026","excerpt":"Company”) announced that the Company’s Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026."},{"id":"e46","sourceId":"filing-7","location":"Succession announcement: issuer account of Diagnostics historical growth","excerpt":"platform into a market-leading franchise, helping grow the business from approximately $6.0 billion in revenue in 2017 to approximately $11.0 billion today, while approximately tripling operating profit."},{"id":"e47","sourceId":"filing-7","location":"Succession announcement: management claim of consistent Diagnostics share gains","excerpt":"Committee of Danaher. “Under her leadership, the Diagnostics platform has consistently gained share in attractive end markets."},{"id":"e48","sourceId":"filing-7","location":"Succession announcement: special equity incentive awards announced","excerpt":"appointment, Danaher has announced special equity incentive awards for key leadership members and founders."},{"id":"e49","sourceId":"filing-3","location":"Proxy compensation: peer selection combines business, talent and investor competition","excerpt":"(TMO) The Committee selected companies for inclusion in this peer group based on (1) the extent to which they compete with us in one or more lines of business, for executive talent and for investors, and (2) comparability of revenues, market capitalization, net income, total assets and number of employees."},{"id":"e50","sourceId":"filing-1","location":"Revenue note: expected recognition schedule of year-end 2025 obligations","excerpt":"The Company expects to recognize revenue on approximately 47% of the remaining performance obligations over the next 12 months, 26% over the subsequent 12 months, and the remainder recognized thereafter."}],"changes":["The uncertain moat verdict is retained after reassessing the current catalog; contractual demand protection and differentiated offerings still do not establish durable competitive barriers.","The supplied August 3, 2026 filing adds a CEO appointment effective October 1, historical Diagnostics growth assertions and announced special equity awards. These do not establish subsequent execution, award vesting or exceptional alignment.","All eight previously graded pricing and management criteria were reassessed against current catalog passages and retain their grades. All four moat criteria remain null."],"limitations":["All sources have dateKind filed. Filing dates are not treated as dates of underlying operating events; the latest supplied filing is dated August 3, 2026.","The catalog lacks quantified switching costs, customer renewal cohorts, product-specific exclusivity duration and reliable comparative market-share outcomes.","Competition passages largely describe generic categories. The named compensation peers were selected for business, executive-talent and investor competition together, so they do not establish product-specific rival coverage; competitor arrays are empty.","Operating results and contractual disclosures support numerical pricing and management assessments. Leadership, DBS effectiveness, share-gain and acquisition-synergy statements remain issuer assertions rather than independently established competitive superiority.","Detailed customer repricing clauses and escalation rights are missing. Contractual pricing freedom is assessed from disclosed procurement constraints and realized price reductions.","Executive ownership information is incomplete in the supplied passages. Announced special equity awards lack sufficient terms and vesting evidence; proposed plan provisions are not treated as proof of adoption.","Several extracted financial tables are incomplete. Assessments use identifiable values and corroborating passages without reconstructing missing entries."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":null,"rationale":"Contractual commitments and specialized workflow offerings establish commercial strengths, but their competitive exclusivity and switching barriers remain unestablished.","evidenceIds":["e1","e2","e5","e6","e15"]},{"criterion":"durability","grade":null,"rationale":"Multiyear obligations protect some demand, but their expected conversion to revenue does not establish an advantage after contract expiry or through technological change.","evidenceIds":["e3","e4","e50","e15"]},{"criterion":"customer_dependency","grade":null,"rationale":"Associated consumables and process services suggest integration into customer workflows. The passages do not establish the operational burden of replacement or dependence on Danaher specifically.","evidenceIds":["e5","e6","e7","e8","e9"]},{"criterion":"erosion_resilience","grade":null,"rationale":"Consumables growth coexists with price pressure, customer demand weakness and intangible impairment. These outcomes do not establish resilience of a durable competitive barrier or prove its absence.","evidenceIds":["e7","e8","e10","e16","e18","e25"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":2,"rationale":"Observed pricing is mixed: consolidated 2025 price contribution was 0.5%; Biotechnology contributed 1.5% in first-half 2026; Life Sciences pricing was insignificant in that period; Diagnostics prices fell 1.0% in 2025.","evidenceIds":["e19","e20","e21","e18"]},{"criterion":"retention","grade":2,"rationale":"Assessed indirectly from contractual minimum purchases, rising remaining obligations and increased consumables demand. These support repeat business, while customer funding weakness and testing variability limit resilience. No retention rate or same-customer renewal result is inferred.","evidenceIds":["e1","e2","e3","e4","e7","e8","e10","e11"]},{"criterion":"margin_resilience","grade":2,"rationale":"Biotechnology first-half operating profit improved, but Diagnostics operating profit declined and consolidated 2025 operating margin fell. Life Sciences comparisons benefit materially from the prior-year impairment. Results demonstrate mixed resilience and do not isolate pricing from mix, costs or acquisition effects.","evidenceIds":["e22","e23","e16"]},{"criterion":"contractual_freedom","grade":1,"rationale":"Centralized purchasing and competitive bidding constrain discretion, with procurement-driven price reductions actually realized and continuing into 2026. Minimum purchase commitments protect demand but do not demonstrate unilateral repricing rights; broader customer escalation terms are missing.","evidenceIds":["e24","e18","e25","e1"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"Actual 2025 cash generation supported research, capital investment and distributions. First-half 2026 acquisition spending of $9.843 billion, acquisition borrowing and $903 million of repurchases increased commitments; compensation issuance adds dilution. A realized trade-name impairment tempers confidence, and acquisition returns remain unproven.","evidenceIds":["e26","e27","e28","e29","e30","e31","e16","e44"]},{"criterion":"incentive_alignment","grade":3,"rationale":"Actual 2025 option and PSU awards, multiyear vesting, additional PSU holding periods, clawbacks, ownership requirements and hedging restrictions establish strong alignment mechanisms. Implemented 2026 changes retain performance equity while adding time-based RSUs and adjusted EPS targets. Actual ownership compliance and realized incentive outcomes remain incomplete; announced special awards do not establish vesting or improved alignment.","evidenceIds":["e32","e33","e34","e35","e36","e48"]},{"criterion":"execution","grade":2,"rationale":"Assessed indirectly from actual growth, consumables demand and cash generation. Second-quarter 2026 core growth improved to 3.0%, but Diagnostics profit weakness and prior impairment make the record mixed. The succession release reports substantial historical Diagnostics growth and claims share gains, without separating acquisitions or proving management causality. The appointment effective October 1 provides no subsequent operating record.","evidenceIds":["e43","e7","e8","e44","e23","e16","e45","e46","e47"]},{"criterion":"governance","grade":2,"rationale":"An independent audit found effective financial reporting controls, and disclosed Board reviews cover capital allocation and performance. The Finance Committee held no 2025 meetings, although Board review provides context. Uncompensated services to aircraft entities controlled by the Rales warrant scrutiny; claimed shared-cost efficiencies do not independently establish fair economics.","evidenceIds":["e37","e38","e39","e40","e41","e42"]}]}],"financialAssessments":[],"qualityPolicy":"quality-scores-2","sourcePolicy":"issuer-evidence-7","basisHash":"b8a68afa7642585faf4fa4f15f57ace02c0f18815c3f1ebeb8e78765880708e6","updatedAt":"2026-10-19T15:46:47.000Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm","publishedAt":"2026-02-24","sha256":"876262eec248f4a11bf3995165d86d2650b881098743a462e6ab667e3ba46347","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000161/dhr-20260626.htm","publishedAt":"2026-07-21","sha256":"44c9f5d6ae0709d9859ee3d9e97d7209e6b8315900e7ee7b536fa7a1b23b881e","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000101/dhr-20260325.htm","publishedAt":"2026-03-25","sha256":"c6f82601678751c14053bdeb0e654b62e81d894c45196190b24ca44cad7ddf21","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000043/dhr-20241231.htm","publishedAt":"2025-02-20","sha256":"78ce5e985616200e228a11c3e7556367e2f21550bed5dba7e0dc6f34267635b6","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000052/dhr-20231231.htm","publishedAt":"2024-02-21","sha256":"7dc62cefcc6fb2fc6100b24d76c0ce25b4b003ff29adc74c4cbcfafcfeabc72c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000107/dhr-20260327.htm","publishedAt":"2026-04-21","sha256":"242b8b48cb0f2db1ae6efa5aa5e2521ab6759a1dee0c004b3de59c5cd4150c49","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/313616/000119312526330652/d161342dex991.htm","publishedAt":"2026-08-03","sha256":"a942aa023935805ca57de84c124018cff468ba9490e24bd6877600351e2733c5","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/dhr-20260721xex991.htm","publishedAt":"2026-07-21","sha256":"0156406214144e01abaec7a9652f1e93b15c4174ebad8942cc684f49a8c569b3","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000109/dhr-20260421xex991.htm","publishedAt":"2026-04-21","sha256":"707d5053eafa10a6f8752720acce30429506c52d34435ed8bf20964a786dfab9","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:44aaff03587033ae0db1ee40d779b53ffbec635156e827367a6223c57fcff173","usage":{"input_tokens":110694,"cached_input_tokens":21120,"cache_write_input_tokens":0,"output_tokens":4092,"reasoning_output_tokens":76}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":60.95134621260993,"operating_margin":25.34546565714868,"roic":null,"fcf_margin":23.98397446779615,"sbc_revenue":0.7401622924659628},"issues":{"ev_sales":"Cash and cash equivalents is unavailable in the extracted statements for this period.","ev_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roiic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","cash":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":60.21098789361634,"operating_margin":27.606367767150708,"roic":null,"fcf_margin":23.408852594452036,"sbc_revenue":1.0676495821549998},"issues":{"ev_sales":"Cash and cash equivalents is unavailable in the extracted statements for this period.","ev_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roiic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","cash":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":58.74424445374634,"operating_margin":21.77480117203851,"roic":null,"fcf_margin":24.198409376308078,"sbc_revenue":1.2808706571787358},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","ev_sales":"Cash and cash equivalents is unavailable in the extracted statements for this period.","ev_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roiic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","cash":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":59.50157068062827,"operating_margin":20.368586387434558,"roic":null,"fcf_margin":22.18219895287958,"sbc_revenue":1.206282722513089},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","ev_sales":"Cash and cash equivalents is unavailable in the extracted statements for this period.","ev_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roiic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","cash":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":59.11348095083034,"operating_margin":19.089873005535658,"roic":null,"fcf_margin":21.40996418104852,"sbc_revenue":1.2129599478997068},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","ev_sales":"Cash and cash equivalents is unavailable in the extracted statements for this period.","ev_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roiic":"Cash and cash equivalents is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","cash":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt":"Cash and cash equivalents is unavailable in the extracted statements for this period.","net_debt_ebitda":"Cash and cash equivalents is unavailable in the extracted statements for this period."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm","publishedAt":"2026-02-24","sha256":"876262eec248f4a11bf3995165d86d2650b881098743a462e6ab667e3ba46347","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000161/dhr-20260626.htm","publishedAt":"2026-07-21","sha256":"44c9f5d6ae0709d9859ee3d9e97d7209e6b8315900e7ee7b536fa7a1b23b881e","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000101/dhr-20260325.htm","publishedAt":"2026-03-25","sha256":"c6f82601678751c14053bdeb0e654b62e81d894c45196190b24ca44cad7ddf21","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000043/dhr-20241231.htm","publishedAt":"2025-02-20","sha256":"78ce5e985616200e228a11c3e7556367e2f21550bed5dba7e0dc6f34267635b6","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000052/dhr-20231231.htm","publishedAt":"2024-02-21","sha256":"7dc62cefcc6fb2fc6100b24d76c0ce25b4b003ff29adc74c4cbcfafcfeabc72c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000107/dhr-20260327.htm","publishedAt":"2026-04-21","sha256":"242b8b48cb0f2db1ae6efa5aa5e2521ab6759a1dee0c004b3de59c5cd4150c49","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/313616/000119312526330652/d161342dex991.htm","publishedAt":"2026-08-03","sha256":"a942aa023935805ca57de84c124018cff468ba9490e24bd6877600351e2733c5","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/dhr-20260721xex991.htm","publishedAt":"2026-07-21","sha256":"0156406214144e01abaec7a9652f1e93b15c4174ebad8942cc684f49a8c569b3","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000109/dhr-20260421xex991.htm","publishedAt":"2026-04-21","sha256":"707d5053eafa10a6f8752720acce30429506c52d34435ed8bf20964a786dfab9","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"history":[{"version":6,"updatedAt":"2026-10-19T18:33:29.802Z","verdict":"uncertain","value":null},{"version":5,"updatedAt":"2026-10-19T13:57:15.039Z","verdict":"uncertain","value":null},{"version":4,"updatedAt":"2026-10-18T16:49:32.080Z","verdict":"uncertain","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"uncertain","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"uncertain","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}